Trasylol news

Martin & Jones has compiled the latest news on the Trasylol recall. We hope you will find these resources helpful.

This page is updated frequently, so we encourage you to visit us often for up-to-date news on the Trasylol recall.

This is the story of a drug that was on the market for 14 years and may have contributed to the deaths of thousands of patients. Trasylol, made by Bayer, is given in the operating room to control bleeding. It was a big money maker.

Bayer marketed Trasylol aggressively until it was used in about one third of all cardiac bypass operations in America.

But then, in 2006, a study showed widespread death associated with Trasylol, and as it turns out there was concern long before that.

Bayer AG halted worldwide sales Monday of its anti-bleeding drug Trasylol at the request of U.S. and foreign health officials pending further analysis of a Canadian study that suggests it's linked to a 50 percent higher risk of death than other drugs in the clinical trial.

The Food and Drug Administration asked the company to stop selling the drug, used to prevent excessive bleeding during heart bypass surgery, until it could receive and review further results from the study. The study comparing the safety and efficacy of the drug with two others was recently halted.

Trasylol data withheld from the Food and Drug Administration (FDA) that showed deadly side effects has caused Bayer to suspended two employees.

Bayer is currently investigating why a study showing that Trasylol can increase the risk of kidney damage, heart failure, stroke, and death was not disclosed at a recent meeting with the FDA. Bayer did not make the study public until more than a week after the meeting.